

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 November 2006 (16.11.2006)

PCT

(10) International Publication Number
WO 2006/121390 A3

(51) International Patent Classification:

C07C 65/10 (2006.01) *C07C 309/30* (2006.01)
A61K 31/192 (2006.01) *C07C 327/16* (2006.01)
A61P 29/00 (2006.01) *C07C 65/32* (2006.01)

[SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). YNGVE, Ulrika [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2006/000547

(22) International Filing Date: 8 May 2006 (08.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0501058-2 9 May 2005 (09.05.2005) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).(71) Applicant (for US only): **MOLIN, Berit** (heiress of the deceased inventor) [SE/SE]; Stadsträdgårdsgatan 61, S-151 68 Södertälje (SE).(72) Inventor: **MOLIN, Håkan** (deceased).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GYBÄCK, Helena** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **HAEBERLEIN, Markus** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **JONASSON, Catrin** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **KIHLSTRÖM, Jacob** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **PLOBECK, Niklas** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **HETTMAN, Andreas** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **VIKLUND, Jenny**

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:

11 January 2007

(48) Date of publication of this corrected version:


15 November 2007

(15) Information about Correction:

see PCT Gazette No. 46/2007 of 15 November 2007

[Continued on next page]

(54) Title: BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR



where D is optionally substituted with G = halo, -NO₂, -CN, -OH, -CF₃, -OCF₃, -NH₂, -CONH₂, -COOH, aryl, heteroaryl, heterocyclic groups, -C₁₋₆alkyl, -C₁₋₆alkoxy, heterocycloalkyl, and C₁₋₆alkylcarboxylate; where D may be connected to G by L = -C(O)-, -S-, or -S(O)₂-; and G may be further substituted with substituents selected from halo, -NO₂, -CN, -OH, -CH₃, -OCH₃, -CF₃, -OCF₃, -NH₂, -CONH₂, -COOH, C₁₋₆alkylcarboxylate; and R₃ = -OH or C₁₋₆alkoxy.

(57) Abstract: Compounds of formula I, wherein Y = H, -OH, halo, -OC₁₋₆alkyl, -C₁₋₆alkyl, the two latter optionally substituted with halo, -CN, -OH, -CF₃, -NH₂; R₁ = -C₃₋₆cycloalkyl, heterocycloalkyl, aryl, alkylaryl, heteroaryl, -C₃₋₆-alkyl, optionally substituted with halo, -CN, -OH, -CF₃, -OCF₃, -NH₂, -CONH₂; M = -C(O)-, -C(H₂)-, -CH(OR^a)-, -N(R^a)-, -S(O)_r-, heteroaryl and a bond; wherein R^a = H or C₁₋₆alkyl and r = 0, 1 or 2; R₂ = H, halo, -CN, or D = -C₁₋₆alkyl, C₃₋₆cycloalkyl, heterocycloalkyl, -N(CH₃)₂, aryl, alkylaryl, heteroaryl, and heterocyclic groups;



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.